Semaglutide is an FDA-approved medication belonging to a class of drugs called GLP-1 receptor agonists
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 16 GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway Authors Xiang J , Qin L , Zhong J, Xia N , Liang Y Received 12 June 2023 Accepted for publication 5 August 2023 Published 15 August 2023 Volume 2023:16 Pages 24332446 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Konstantinos Tziomalos Jie Xiang, 1 Liyan Qin, 2 Jinling Zhong, 3 Ning Xia, 2 Yuzhen Liang 3 1 Department of Clinical Nutrition, The First Affiliated Hospital of Guangxi Medical University, Nanning, Peoples Republic of China
Sleep disturbances Some people report insomnia on semaglutide , particularly at higher doses
Get enough protein
Its effectiveness, demonstrated in clinical trials, showcases substantial weight loss results that have redefined expectations
Special Note About Pediatric Language You May See Online Some online text mentions pediatric weight programs and activity requirements